These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 29187194)

  • 1. Treatment effects of renin-angiotensin aldosterone system blockade on kidney failure and mortality in chronic kidney disease patients.
    Vejakama P; Ingsathit A; McKay GJ; Maxwell AP; McEvoy M; Attia J; Thakkinstian A
    BMC Nephrol; 2017 Nov; 18(1):342. PubMed ID: 29187194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis.
    Onuigbo MA; Onuigbo NT
    QJM; 2008 Jul; 101(7):519-27. PubMed ID: 18375475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The renin-angiotensin-aldosterone system blockade in patients with advanced diabetic kidney disease.
    Bermejo S; García CO; Rodríguez E; Barrios C; Otero S; Mojal S; Pascual J; Soler MJ
    Nefrologia (Engl Ed); 2018; 38(2):197-206. PubMed ID: 29102270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal failure and concurrent RAAS blockade in older CKD patients with renal artery stenosis: an extended Mayo Clinic prospective 63-month experience.
    Onuigbo MA; Onuigbo NT
    Ren Fail; 2008; 30(4):363-71. PubMed ID: 18569908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?
    Silvariño R; Rios P; Baldovinos G; Chichet MA; Perg N; Sola L; Saona G; De Souza N; Lamadrid V; Gadola L
    Nephron; 2019; 143(2):100-107. PubMed ID: 31203280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does renin-angiotensin aldosterone system blockade exacerbate contrast-induced nephropathy in patients with chronic kidney disease? A prospective 50-month Mayo Clinic study.
    Onuigbo MA; Onuigbo NT
    Ren Fail; 2008; 30(1):67-72. PubMed ID: 18197546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mineral Metabolites, Angiotensin II Inhibition and Outcomes in Advanced Chronic Kidney Disease.
    Jovanovich AJ; Chonchol MB; Sobhi A; Kendrick JB; Cheung AK; Kaufman JS; Smits G; Jablonski KL;
    Am J Nephrol; 2015; 42(5):361-8. PubMed ID: 26606453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pentoxifylline Decreases Dialysis Risk in Patients With Advanced Chronic Kidney Disease.
    Wu PC; Wu CJ; Lin CJ; Pan CF; Chen CY; Huang TM; Wu CH; Lin SL; Chen YM; Chen L; Wu VC; ;
    Clin Pharmacol Ther; 2015 Oct; 98(4):442-9. PubMed ID: 26082272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of renin-angiotensin-aldosterone system blockade in adults with diabetes mellitus and advanced chronic kidney disease not on dialysis: a systematic review and meta-analysis.
    Nistor I; De Sutter J; Drechsler C; Goldsmith D; Soler MJ; Tomson C; Wiecek A; Donciu MD; Bolignano D; Van Biesen W; Covic A
    Nephrol Dial Transplant; 2018 Jan; 33(1):12-22. PubMed ID: 29106631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined blockade of renin-angiotensin-aldosterone system reduced all-cause but not cardiovascular mortality in dialysis patients: A mediation analysis and systematic review.
    Li SM; He WB; Chen J; Cai QQ; Huang FF; Zhang K; Wang JF; Liu X; Huang H
    Atherosclerosis; 2018 Feb; 269():35-41. PubMed ID: 29258005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of Renin-Angiotensin-Aldosterone System blockade in patients admitted to hospital with confirmed coronavirus disease (COVID-19) infection (The McGill RAAS-COVID- 19): A structured summary of a study protocol for a randomized controlled trial.
    Aflaki M; Flannery A; Ferreira JP; Cheng MP; Kronfli N; Marelli A; Zannad F; Brophy J; Afillalo J; Huynh T; Giannetti N; Bessissow A; Ezekowitz JA; Lopes RD; Ambrosy AP; Craig M; Sharma A
    Trials; 2021 Feb; 22(1):115. PubMed ID: 33546734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Impact of Renin-Angiotensin System Blockade on Renal Outcomes and Mortality in Pre-Dialysis Patients with Advanced Chronic Kidney Disease.
    Oh YJ; Kim SM; Shin BC; Kim HL; Chung JH; Kim AJ; Ro H; Chang JH; Lee HH; Chung W; Lee C; Jung JY
    PLoS One; 2017; 12(1):e0170874. PubMed ID: 28122064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does concurrent renin-angiotensin-aldosterone blockade in (older) chronic kidney disease patients play a role in the acute renal failure epidemic in US hospitalized patients?--Three cases of severe acute renal failure encountered in a northwestern Wisconsin Nephrology practice.
    Onuigbo MA
    Hemodial Int; 2009 Oct; 13 Suppl 1():S24-9. PubMed ID: 19775421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Renin-Angiotensin System Blockade in Advanced CKD: An NKF-KDOQI Controversies Report.
    Weir MR; Lakkis JI; Jaar B; Rocco MV; Choi MJ; Kramer HJ; Ku E
    Am J Kidney Dis; 2018 Dec; 72(6):873-884. PubMed ID: 30201547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin receptor blockers are associated with lower mortality than ACE inhibitors in predialytic stage 5 chronic kidney disease: A nationwide study of therapy with renin-angiotensin system blockade.
    Lin CC; Wu YT; Yang WC; Tsai MJ; Liu JS; Yang CY; Li SY; Ou SM; Tarng DC; Hsu CC
    PLoS One; 2017; 12(12):e0189126. PubMed ID: 29216260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conservative management of chronic kidney disease stage 5: role of angiotensin converting enzyme inhibitors.
    Dattolo PC; Gallo P; Michelassi S; Paudice N; Cannavò R; Romoli E; Fani F; Tsalouchos A; Mehmetaj A; Ferro G; Sisca S; Pizzarelli F
    J Nephrol; 2016 Dec; 29(6):809-815. PubMed ID: 27015900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Renin-Angiotensin-Aldosterone System Blockade in Patients with End-Stage Renal Disease.
    Slomka T; Lennon ES; Akbar H; Gosmanova EO; Bhattacharya SK; Oliphant CS; Khouzam RN
    Am J Med Sci; 2016 Mar; 351(3):309-16. PubMed ID: 26992264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan.
    Wu LS; Chang SH; Chang GJ; Liu JR; Chan YH; Lee HF; Wen MS; Chen WJ; Yeh YH; Kuo CT; See LC
    Cardiovasc Diabetol; 2016 Apr; 15():56. PubMed ID: 27039185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.
    Hsu TW; Liu JS; Hung SC; Kuo KL; Chang YK; Chen YC; Hsu CC; Tarng DC
    JAMA Intern Med; 2014 Mar; 174(3):347-54. PubMed ID: 24343093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Dual Blockade of the Renin-Angiotensin-Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis.
    Feng Y; Huang R; Kavanagh J; Li L; Zeng X; Li Y; Fu P
    Am J Cardiovasc Drugs; 2019 Jun; 19(3):259-286. PubMed ID: 30737754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.